| Aspect | Summary of ABCA7 functional annotation | Evidence / examples | Key citations |
|---|---|---|---|
| Verified identity | ABCA7 in this report refers to human **ATP-binding cassette subfamily A member 7** / **phospholipid-transporting ATPase ABCA7** (UniProt Q8IZY2), a full-length ABCA-family ABC transporter with two TMDs, two NBDs, large extracellular domains, and regulatory domains. | Recent structural work explicitly analyzed **human ABCA7 isoform 1** and described it as an ABCA-family phospholipid exporter/translocator linked to Alzheimer’s disease. | (pqac-00000000, pqac-00000004, pqac-00000008) |
| Primary molecular function / enzyme activity | ABCA7 is an **ATP-dependent lipid transporter** whose best-supported primary biochemical role is **phospholipid translocation/extrusion across the plasma membrane**, with more limited cholesterol export than ABCA1. It is not a soluble enzyme acting on a small-molecule substrate; rather, ATP hydrolysis powers membrane lipid movement. | Cryo-EM and ATPase studies show ATP-dependent conformational cycling; older functional studies and reviews indicate ABCA7 exports phospholipids and can generate HDL-like particles with apolipoprotein acceptors, but is less efficient than ABCA1 for cholesterol efflux. | (pqac-00000000, pqac-00000001, pqac-00000013, pqac-00000007, pqac-00000009) |
| ATPase / catalytic mechanism | ATP hydrolysis occurs at the two cytoplasmic NBDs and drives transitions between **open** and **nucleotide-bound closed** conformations. In nanodiscs/liposomes, ABCA7 ATPase activity follows Michaelis-Menten kinetics; catalytic glutamate mutations strongly reduce activity. | Le et al. showed ATPase activity in detergent, liposomes, and nanodiscs, with reduced activity in the hydrolysis-deficient **E965Q/E1951Q** mutant and structural capture of open and ATP-bound closed states. | (pqac-00000000, pqac-00000001, pqac-00000002) |
| Supported lipid substrates | The strongest evidence supports **phospholipids** as primary substrates, especially **phosphatidylcholine (PC)**, **phosphatidylserine (PS)**, **sphingomyelin**, and **lysophosphatidylcholine**; ABCA7 can also transport/export **cholesterol**, but generally less robustly than ABCA1. | Reviews summarizing cell-based efflux work report ABCA7 preferentially transfers phospholipids to HDL-like particles and acceptors, while cholesterol efflux is modest; structural work could not assign exact phospholipid identity in the TMD but showed lipids occupying the transport pathway. | (pqac-00000007, pqac-00000009, pqac-00000001) |
| Lipid specificity details | Lipid composition modulates ABCA7 activity: ATPase activity is highest in **PE** and **PS** nanodiscs, lower in **PC**; cholesterol in nanodiscs inhibited ATPase under tested conditions. ABCA7 has been linked to **PS flipping** and **PC extrusion**, consistent with effects on membrane asymmetry. | Structural/biochemical work found highest ATPase stimulation in PE and PS nanodiscs; discussion linked prior reports of higher PS translocation to the outer leaflet and higher PC extrusion. | (pqac-00000001, pqac-00000013) |
| Transport direction / mechanism of lipid movement | Current model supports a dual but related role in **(i) phospholipid flipping from the cytoplasmic to extracellular leaflet** and **(ii) lipid extrusion from the extracellular leaflet toward the ECD and apolipoprotein acceptors**. | The 2023 cryo-EM study proposed a “bellows-like” mechanism in which TMD opening draws in bilayer lipids and closure expels them upward/back out; reviews note that exact substrate identity and the relationship between flipping and extrusion remain unresolved. | (pqac-00000012, pqac-00000013, pqac-00000004) |
| Structural mechanism | In the open state, an ordered patch/file of bilayer lipids traverses the TMD; in the ATP-bound closed state, the TMD becomes lipid-free except for a small extracellular **exit pocket**. Positively charged residues near the ECD/TMD interface likely help guide phospholipid headgroups. | Cryo-EM resolved lipid density inside the TMD in open nanodisc-reconstituted ABCA7 and a closed ATP-bound state with a putative lipid exit pocket; mutating ECD basic residues lowered ATPase activity. | (pqac-00000001, pqac-00000002, pqac-00000013) |
| Subcellular localization | ABCA7 localizes primarily to the **plasma membrane**, where it performs lipid translocation/efflux; it is also detected intracellularly, including the **endoplasmic reticulum (ER)**. An alternative splice isoform is reported mainly in the ER. | Full-length ABCA7 has cell-surface and intracellular localization; type II splice isoform is ER-restricted. Missense variants can exclude ABCA7 from the plasma membrane and retain it in the ER. | (pqac-00000007, pqac-00000006) |
| Localization defects in disease variants | Pathogenic missense variants can impair ABCA7 function by **mislocalization**, reducing the amount of transporter at the plasma membrane rather than necessarily abolishing expression. | In HeLa-cell assays, several AD-associated missense variants showed decreased plasma membrane localization and increased ER retention. | (pqac-00000006) |
| Tissue and cell-type expression | ABCA7 is highly expressed in **myelo-lymphatic tissues** and immune cells, including **macrophages**, **B cells**, and **NK cells**; in the brain it is expressed in **neurons, microglia, astrocytes, endothelial cells/BBB, and pericytes**. | Reviews summarize expression in peripheral leukocytes, thymus, spleen, bone marrow, fetal tissues, and multiple human/mouse brain cell types. Human iPSC-based work notes abundant neuronal expression. | (pqac-00000008, pqac-00000007, pqac-00000003) |
| Lipid metabolism pathway role | ABCA7 participates in **cellular lipid homeostasis**, especially phospholipid handling and limited cholesterol efflux to apolipoprotein acceptors such as **apoA-I** and **apoE**, contributing to HDL-like particle formation and membrane lipid organization. | ABCA7 shares strong homology with ABCA1, binds apoA-I/apoE in cellular studies, and transfers phospholipids efficiently; endogenous ABCA7 is thought to function more in host defense/phagocytosis than in classic HDL biogenesis. | (pqac-00000007, pqac-00000009, pqac-00000004) |
| Phagocytosis / innate immunity role | ABCA7 supports **phagocytosis of apoptotic cells** and likely contributes to microglial/macrophage engulfment by shaping membrane lipid asymmetry and/or receptor-containing membrane domains. | Reviews summarize reduced phagocytic activity in ABCA7-deficient macrophages and relocalization with LRP1 at the plasma membrane in the presence of apoptotic cells. | (pqac-00000007, pqac-00000009, pqac-00000005) |
| Membrane organization role | ABCA7 likely regulates **plasma membrane asymmetry**, **lipid raft/nanodomain composition**, and local bilayer structure, which can influence receptor signaling and phagocytic competence. | Structural and review evidence links ABCA7-mediated lipid translocation with altered outer leaflet PS/PC distribution and immune membrane organization. | (pqac-00000013, pqac-00000005) |
| Mitochondrial lipid metabolism role | ABCA7 deficiency alters **mitochondria-related phospholipids**, particularly **phosphatidylglycerol** and **cardiolipin**, causing abnormal mitochondrial morphology, reduced ATP synthase activity/respiration, higher ROS, and downstream neuronal/synaptic dysfunction. | In human iPSC-derived cortical organoids and neurons, ABCA7 knockout reduced phosphatidylglycerol and cardiolipin; phosphatidylglycerol or NMN partially rescued phenotypes. | (pqac-00000003) |
| Amyloid / APP metabolism role | ABCA7 is implicated in Alzheimer-relevant **APP processing**, **amyloid deposition**, and possibly **Aβ clearance**, though the dominant mechanism remains unsettled and may vary by context (lipid transport, microglial phagocytosis, or both). | Genetic association, CSF biomarker, and review literature support altered APP processing and amyloid-related biomarker changes in mutation carriers; multiple studies associate ABCA7 dysfunction with increased amyloid pathology. | (pqac-00000004, pqac-00000005, pqac-00000014) |
| Regulation by sterol-sensing pathways | ABCA7 expression is regulated differently from ABCA1: a key model proposes **negative regulation by the SREBP system**, so reduced cellular cholesterol can increase ABCA7-linked host-defense functions. Regulation may be cell-type specific. | Abe-Dohmae and Yokoyama reviewed SREBP-dependent negative regulation; later work in human neural cell lines found cholesterol depletion reduced ABCA7 in microglia/astrocytes, highlighting context dependence. | (pqac-00000009, pqac-00000004) |
| Alternative splicing / isoforms | At least two isoforms are discussed in the literature. The shorter **type II ABCA7** has a different N-terminus, shows tissue-dependent expression, and is mainly ER-localized, suggesting non-identical functions versus canonical ABCA7. | Full-length ABCA7 is enriched in brain and bone marrow, whereas type II is more abundant in lymph node, spleen, thymus, and trachea. | (pqac-00000007) |
| Major disease association | ABCA7 is a **major genetic risk gene for late-onset Alzheimer’s disease (LOAD)** and is among the stronger common/rare variant contributors identified after APOE in some populations. | Multiple reviews summarize GWAS and sequencing evidence connecting common SNPs, PTC variants, missense variants, and VNTR expansion with AD risk. | (pqac-00000004, pqac-00000005, pqac-00000014) |
| Disease-associated variant classes | Pathogenic classes include **premature termination codon (PTC) variants** (nonsense, frameshift, canonical splice), **VNTR expansion**, and damaging **missense** variants. Proposed mechanisms include **haploinsufficiency**, altered splicing, and plasma membrane exclusion/mislocalization. | Reviews and cohort studies note NMD/haploinsufficiency for many PTC alleles; missense mutations can cause ER retention and plasma membrane exclusion. | (pqac-00000006, pqac-00000014) |
| Disease statistics / effect sizes | In reviewed cohorts, AD-enriched ABCA7 PTC variants show odds ratios roughly **1.4–5.3** depending on ancestry/study design; in Caucasian cohorts ORs around **1.7–2.6** were summarized, while some African American variants have especially high frequency/effect. | Duchateau et al. summarized frequencies and ORs across cohorts and highlighted the strong impact of African ancestry variants such as the 44-bp deletion background. | (pqac-00000014, pqac-00000005) |
| Ancestry-related findings | ABCA7-associated AD risk is particularly important in **African American / African ancestry** populations, where some variants may confer effect sizes comparable to or stronger than APOE ε4 in specific studies. | Reviews emphasize higher burden/frequency of certain ABCA7 risk variants in African American cohorts and stronger association signals than typically seen in European cohorts. | (pqac-00000005, pqac-00000014) |
| Functional interpretation | Overall, the most evidence-supported annotation is that ABCA7 is a **plasma-membrane, ATP-driven phospholipid translocator/exporter** whose lipid-remodeling activity connects **membrane homeostasis**, **phagocytosis/innate immunity**, **neuronal mitochondrial lipid balance**, and **AD-related amyloid biology**. | This integrates structural, biochemical, expression, genetic, and iPSC-neuronal evidence. Important unresolved questions remain about precise endogenous substrates and the relative contribution of lipid export versus phagocytic signaling in disease. | (pqac-00000000, pqac-00000003, pqac-00000004, pqac-00000013) |


*Table: This table summarizes the current functional annotation of human ABCA7, including its biochemical activity, substrates, localization, pathways, expression, regulation, and disease relevance. It is useful as a compact evidence-based reference connecting structural, cellular, and genetic findings.*